|
| Primary information |
|---|
| ID | 10696 |
| Therapeutic ID | Th1158 |
| Protein Name | Aprotinin |
| Sequence | >Th1158_Aprotinin
RPDFCLEPPYTGPCKARIIRYFYNAKAGLCQTFVYGGCRAKRNNFKSAEDCMRTCGGA
|
| Molecular Weight | 6511.439 |
| Chemical Formula | C284H432N84O79S7 |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting point | >100 |
| Half-life | Plasma half life: 150 minutes, Elimination half life: 10hrs |
| Description | NA |
| Indication/Disease | NA |
| Pharmacodynamics | NA |
| Mechanism of Action | NA |
| Toxicity | NA |
| Metabolism | Aprotinin is slowly degraded by lysosomal enzymes. |
| Absorption | 100% (IV) |
| NA |
| Clearance | NA |
| Categories | NA |
| Patents Number | CA2030783 |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | Heparin- Aprotinin, in the presence of heparin, has been found to prolong the activated clotting time (ACT) as measured by a celite surface activation method |
| Target | Trypsin-1,Chymotrypsinogen B,Plasminogen,Kallikrein-1 |
| Brand Name | NA |
| Company | NA |
| Brand Description | NA |
| Prescribed For | NA |
| Chemical Name | NA |
| Formulation | NA |
| Physical Appearance | NA |
| Route of Administration | NA |
| Recommended Dosage | NA |
| Contraindication | NA |
| Side Effects | NA |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |